| Title |
|
A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
| Type of document |
|
| OrcId |
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
| DOI |
|
10.1038/s41436-019-0582-2 |
|
|
| Abstract |
|
To assess the relative cost-effectiveness of cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy (DCM) compared with periodical clinical surveillance. A decision-analytic model, combining a decision tree and a Markov model, was used to determine the lifetime costs and quality-adjusted life years (QALYs) for the two strategies. Deterministic and probabilistic sensitivity analyses were undertaken to assess the robustness of findings and to explore decision uncertainty. The incremental cost per additional QALY of cascade genetic testing prior to periodical clinical surveillance of first-degree relatives compared with periodical clinical surveillance alone was estimated at approximately AUD $6100. At established thresholds of cost-effectiveness, there is a 90% probability that cascade genetic testing is cost-effective. Extensive sensitivity analyses, including the addition of second-degree relatives, did not alter the conclusions drawn from the main analysis. Using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with DCM is very likely to be cost-effective. As the DCM pathogenic variant detection rate rises and new evidence for personalized treatment of at-risk individuals becomes available, the cost-effectiveness of cascade testing will further increase. |
|
|
| Link |
|
| Citation |
|
Genetics in Medicine : Official Journal of the American College of Medical Genetics 2019; 21(12): 2815-2822 |
|
|
| Jornal Title |
|
Genetics in Medicine : Official Journal of the American College of Medical Genetics |
|
|
